Copyright
©The Author(s) 2017.
World J Diabetes. Jul 15, 2017; 8(7): 381-389
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.381
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.381
Table 8 Insulin dose (U/d) before and after autologous bone marrow derived stem cell therapy in Group II
| Patient | Baseline | 3 mo | 6 mo | 12 mo |
| 1 | 40 | 27 | 16 | 12 |
| 2 | 46 | 44 | 38 | 34 |
| 3 | 25 | 18 | 8 | 5 |
| 4 | 30 | 20 | 20 | 18 |
| 5 | 40 | 34 | 30 | - |
| 6 | 55 | 40 | - | - |
| 7 | 45 | 27 | - | - |
| Mean ± SE | 40 ± 4 | 30 ± 4 | 22 ± 5 | |
| P value | 0.003 | 0.01 |
- Citation: Sood V, Bhansali A, Mittal BR, Singh B, Marwaha N, Jain A, Khandelwal N. Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods. World J Diabetes 2017; 8(7): 381-389
- URL: https://www.wjgnet.com/1948-9358/full/v8/i7/381.htm
- DOI: https://dx.doi.org/10.4239/wjd.v8.i7.381